Board of Directors
Michael is a co-founder and Chairman of the Board of Tarsus. He is also co-founder, former-CEO and serves on the board of Presidio Medical. He formerly served as Chairman of Oyster Point Pharma, Inc. (NASDAQ: OYST). He was also previously Vice President, Neurostimulation for Allergan (an AbbVie company) after serving as CEO of Oculeve, Inc., which was acquired by Allergan. He received a B.E. degree in biomedical engineering from Vanderbilt University and M.S. and Ph.D. degrees in biomedical engineering from Case Western Reserve University. He is a graduate of Stanford University’s Biodesign Fellowship and Vision Research Fellowship. He has numerous patents and peer-reviewed publications.
Bobby has served as President and CEO of Tarsus Pharmaceuticals since co-founding the company in 2017. In that time, Tarsus has established a leading team and culture, and completed successful fundraising efforts through an IPO and global partnerships. Tarsus continues to advance its pipeline into clinical studies, including its lead product, TP-03, which is now in Phase 3 clinical trials and commercial planning.
Bobby also serves on the board and is Co-Chairman of Vibrato Medical, a medical device company developing a wearable treatment for peripheral arterial diseases, which has received NIH grant awards and generated first-in-human proof of concept clinical data. Previously, he was President and CMO of Metavention, a medical device company developing an interventional treatment for metabolic diseases, from inception through proof of concept clinical trials as well as Series A through Series C fundraising.
Bobby began his biotechnology career at Versant Ventures and Third Rock Ventures, where he was an investor and board observer in numerous life sciences companies. He also served on the board of the nonprofit organization Octane. He trained as a physician scientist, completing his residency in internal medicine and serving as an attending hospitalist at Brigham and Women’s Hospital. He received an MD from Harvard Medical School (Harvard-MIT Heath Sciences and Technology), a PhD in chemistry from Oxford University as a Rhodes Scholar, and a BA in physics from Rice University. He is also an author of numerous patents and peer-reviewed publications.
Bhaskar is Operating Partner at Frazier Healthcare Partners where he joined in 2011 and brings to the Life Sciences team significant operational experience in drug research, development, and commercialization in the United States, Europe, and emerging markets. He leads investments in later-stage companies and in international opportunities and is a co-founder of Arcutis (NASDAQ: ARQT), where he currently serves on the Board. Bhaskar also serves on the Board of Teligent (NASDAQ: TLGT) and is an advisor to the Johns Hopkins Berman Institute of Bioethics. Bhaskar also served on the board of directors of Silvergate Pharmaceuticals (acquired by CutisPharma), Corium International (acquired by Gurnet Point Capital) and Thesan Pharmaceuticals.
Prior to joining Frazier, Bhaskar was President of Valeant Pharmaceuticals, where he led Valeant’s international operations and business development activities. He joined Valeant through its acquisition of Dow Pharmaceutical Sciences, where he had been President and CEO. Before Dow, Bhaskar worked at Mylan Pharmaceuticals in several capacities including EVP of Scientific Affairs at Mylan subsidiary Bertek Pharmaceuticals, and as General Manager of the Dermatology Division. Earlier, he worked at Penederm, a skin-products and drug-delivery company, as VP of R&D.
Bhaskar holds a Ph.D. in Pharmaceutics, a M.S. in Industrial Pharmacy and a B.S. in Pharmacy.
Rose has more than 30 years of extensive experience in the pharmaceutical industry, including executive leadership, board service, innovation, business development, and global commercialization. She brings significant executive leadership and operating expertise to the Tarsus board, having previously served as President and Chief Executive Officer of both MELA Sciences, Inc. (now Strata Skin Sciences) and epocrates, as well as Partner and Head of Commercialization at Appletree Partners. Prior to that, Rose held several senior executive positions at Johnson & Johnson, including Group Chairman, OTC & Nutritional Group, leading the largest worldwide OTC company. Earlier in her career, she spent 20 years at Bristol Myers Squibb, completing her tenure as President, US Primary Care.
Rose currently sits on the boards of Teva Pharmaceuticals Industries Ltd., Catalent, Inc., and Certara, Inc. as well as acts as a director of the Hackensack Meridian Health Center for Discovery and Innovation. Previously, she served on the boards of several pharmaceutical and life sciences companies, including Edge Therapeutics, Inc., Unilife Corporation, Cipher Pharmaceuticals Inc., Targanta Therapeutics Corp., and Zealand Pharma A/S. Rose received a BA in both communications and English from the State University of New York at Oswego and an MBA from Kent State University.
Andrew is a Managing Director at Marshall Wace and helps lead the XO Healthcare Innovation fund, which focuses on late-stage private investments. Before this he was a Partner on the private innovation team at Palo Alto-based Vivo Capital, where he focused on private pharmaceutical and medical device companies. Prior to Vivo, he worked at McKinsey & Company in their Silicon Valley office in their pharmaceutical and medical products practice. He has served on the boards of several healthcare companies, including Swift Health Systems Inc (Chairman), Ossium Health (Director), Arcutis Biotherapeutics (NASDAQ: ARQT) (Observer), Instil Bio (NASDAQ: TIL) (Observer), Harmony Biosciences (NASDAQ: HRMY) (Observer), Neocis (Observer) and Impel Neuropharma (NASDAQ: IMPL) (Observer). Other representative investments include River Vision (acquired by Horizon).
Andrew is a US board-certified physician in both Critical Care Medicine and Emergency Medicine. He received his MD from The George Washington University School of Medicine in Washington, DC, and has held academic and clinical appointments at the Mayo Clinic, Stanford VA Palo Alto Medical Center, Oregon Health & Science University, the University of Arizona, and the Washington Township Medical Foundation.
Bill is Founder and Managing Partner of Flying L Partners and a Founder and Managing Director of Versant Ventures. He has over two decades of operations experience in the healthcare industry and specializes in early-stage investing in medical devices. Prior to co-founding Versant Ventures, Bill was a general partner at Brentwood Venture Capital. He was previously Founder, Chairman, and CEO of Chiron Vision, which was sold to Bausch and Lomb in 1997. Prior to Chiron Vision, Bill founded and served as President of American Medical Optics, a division of American Hospital Supply Corporation, which was sold to Allergan in 1986. Later, he served on the board of their successor company, Advanced Medical Optics, which was acquired by Abbott in 2009 and then by Johnson and Johnson in 2016.
Before entering the healthcare industry, he was an assistant professor in the Department of Surgery at the Indiana University School of Medicine. Bill currently serves on the boards of several private companies. He previously served on the board of Edwards Lifesciences (NYSE: EW), Glaukos (NYSE: GKOS) and Oyster Point Pharma, Inc. (NASDAQ: OYST). He received his BS, MS, and PhD from Purdue University.
Wendy has more than 30 years of experience in the biopharmaceutical industry, as a public company director and product commercialization leader, including 26 years at Merck & Co. Inc.
While at Merck, Wendy held positions of increasing seniority, most recently as Chief Marketing Officer. In that position, she led a global organization charged with all aspects of commercialization of pharmaceuticals in more than 20 therapeutic areas. She also served as General Manager, Cardiovascular/Metabolic U.S. Business Unit, and as Merck’s Senior Vice President of Human Resources. Earlier in her career, she was Vice President of the Women’s Health Care franchise for Johnson & Johnson’s Ortho-McNeil Pharmaceutical subsidiary.
Wendy has served on the boards of several public and private biotechnology and medical device companies, including St. Jude Medical, Medivation, Alder Biopharmaceuticals, Aratana Therapeutics, and Myokardia. She currently serves on the boards of Global Blood Therapeutics, Ideaya Biosciences, and Inovio Pharmaceuticals. Wendy received a B.S. in business administration from Portland State University and an M.B.A. from Temple University, Fox School of Business.
Elizabeth is Chief Medical Advisor at Tarsus, partner at Virginia Eye Consultants, and Medical Director at Virginia Surgery Center. With more than two decades of experience in eye care, she’s authored hundreds of articles and conducted numerous lectures on subjects such as refractive cataract surgery, anterior segment reconstruction, and external disease management. Elizabeth provides guidance and governance across several national medical boards and committees, including as an examiner for the American Board of Ophthalmology and as the Chair of the Cataract Section of Ophthalmic News & Education (ONE) Network for the American Academy of Ophthalmology (AAO). Dr. Yeu is also an Executive Committee member and the current Secretary for the American Society of Cataract and Refractive Surgery (ASCRS) and, in 2023, she will become ASCRS President.
Elizabeth currently serves on the boards of Tarsus, STAAR Surgical, Ocular Science, Avellino Lab USA, and the Virginia Eye Foundation. She also serves as an Executive Board Member of CVP Physicians, Mid Atlantic. She earned her MD through an accelerated and combined undergraduate/medical school program at the University of Florida College of Medicine. Elizabeth completed her ophthalmology residency at Rush University Medical Center in Chicago, where she served as Chief Resident (2006-2007). She then accepted a fellowship in Cornea, Anterior Segment, and Refractive Surgery at the Cullen Eye Institute, Baylor College of Medicine (2007-2008), where she also served as an Assistant Professor (2008-2013). Elizabeth continues to train residents as Assistant Professor of Ophthalmology at Eastern Virginia Medical School.